Home Compare ABBV vs GILD
Stock Comparison · Industry comparison · Drug Manufacturers - General

AbbVie vs Gilead Sciences: Which Stock Looks Stronger in 2026?

Gilead Sciences holds the cleaner structural position, with valuation as the main driver and profitability adding further support. AbbVie does not offset that deficit through any equally strong structural edge elsewhere. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.

Updated 2026-08-16

Valuation still does most of the heavy lifting in this comparison. The overall score gap is 23 points in favour of Gilead Sciences, Inc..

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. ABBV and GILD share the same industry classification.

For a similarity-based comparison, see how AbbVie and Gilead Sciences each position within their functional peer groups in AssetNext.

Peer-Relative Score
ABBV
AbbVie Inc.
52
Peer-Score
Signal qualityHigh
Peer basis: S&P 500
vs
GILD
Gilead Sciences, Inc.
75
Peer-Score
Signal qualitylow
Peer basis: S&P 500

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing and operating quality both support the lead here.

Dimension spread: ABBV vs GILD Profitability 43 64 Stability 68 69 Valuation 27 84 Growth 84 82 ABBV GILD
Gap Ranking
#1 Valuation +57
#2 Profitability +21
#3 Growth +2
#4 Stability +1
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ABBV and GILD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ABBVGILD Relative valuation Structural strength

The two profiles are relatively close, but the price setup still leans toward Gilead Sciences, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) and Forward P/E where available.

Entry today — historical context

Where ABBV and GILD each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY ABBV Elevated · above norm 0th 50th 100th 1 pct gap GILD Elevated · above norm 0th 50th 100th 98th 97th
ABBV (98th percentile) and GILD (97th percentile) both sit in the upper portion of their own 5-year ranges. The historical entry context is broadly similar for both. This reflects entry timing, not which company is structurally stronger.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Valuation
Gilead Sciences, Inc. ranks near the top of the group on valuation; AbbVie Inc. sits in the weaker half.
Profitability
On profitability, the edge still sits with Gilead Sciences, Inc., even though both profiles look solid.
Valuation — Dominant Gap
ABBV
27
GILD
84
Gap+57in favour of GILD

The peer-relative valuation gap is very wide, with the stronger side also looking meaningfully cheaper.

What else supports the lead

Capital efficiency adds support, with a 17.9-point ROIC advantage.

What this means for the comparison

Valuation is the clearest driver, and profitability also supports Gilead Sciences, Inc.'s broader structural position.

Explore full peer positioning in AssetNext

Break down the ABBV vs GILD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-driven comparisons

Explore how ABBV and GILD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.